HC Wainwright Has Positive Outlook for FULC Q1 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for Fulcrum Therapeutics in a research note issued to investors on Tuesday, February 24th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.28) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.79 EPS.

A number of other equities research analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus set a $25.00 price objective on Fulcrum Therapeutics in a research note on Monday, December 8th. Bank of America lifted their target price on Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Fulcrum Therapeutics in a report on Monday, January 12th. They set an “overweight” rating and a $20.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Fulcrum Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Fulcrum Therapeutics Trading Up 4.7%

FULC opened at $8.98 on Thursday. Fulcrum Therapeutics has a 1-year low of $2.32 and a 1-year high of $15.74. The company has a market cap of $486.00 million, a price-to-earnings ratio of -7.61 and a beta of 3.19. The company’s fifty day moving average price is $10.73 and its two-hundred day moving average price is $9.48.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31).

Insider Buying and Selling

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the transaction, the insider owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert J. Gould sold 15,000 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the transaction, the director directly owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC boosted its position in Fulcrum Therapeutics by 21.9% during the fourth quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company’s stock worth $74,206,000 after purchasing an additional 1,180,111 shares during the period. Nantahala Capital Management LLC lifted its stake in shares of Fulcrum Therapeutics by 8.9% during the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock valued at $42,971,000 after buying an additional 382,485 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Fulcrum Therapeutics by 53.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after buying an additional 1,589,000 shares during the period. Braidwell LP grew its stake in Fulcrum Therapeutics by 1,294.7% in the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock valued at $34,622,000 after buying an additional 2,841,734 shares in the last quarter. Finally, Siren L.L.C. bought a new stake in Fulcrum Therapeutics during the 4th quarter valued at $22,054,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics News Summary

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: Phase 1b PIONEER (20 mg) data showed a large mean absolute HbF increase (from 7.1% to 19.3% at Week 12), improvements in hemolysis and hemoglobin, 7/12 patients reached ≥20% HbF, 58% had zero VOCs during treatment, and no treatment-related SAEs; company plans a potential registration‑enabling trial in H2 2026. Read More.
• Positive Sentiment: HC Wainwright initiated or reiterated bullish modeling with a Buy rating and $25 price target, projecting FY2030 EPS of $2.71 — a materially higher long‑term view than consensus and supportive for upside if clinical development progresses. Read More.
• Positive Sentiment: Stifel commented that the prior share move lower was “overdone,” signaling some sell‑side support for a rebound and reduced downside risk from the recent pullback. Read More.
• Neutral Sentiment: Q4 2025 results: Fulcrum reported (‑$0.31) EPS, in line with consensus; management held a conference call and reiterated development plans — meeting estimates removes an earnings disappointment but leaves focus squarely on clinical progress and the next trials. Read More.
• Neutral Sentiment: Earnings call transcript and investor Q&A are available for detail on runway, timing for a registration‑enabling study and safety/efficacy readouts — items investors will watch for upcoming catalysts. Read More.
• Negative Sentiment: Some headlines noted that the stock still tumbled at points despite the positive trial readout, indicating profit‑taking, short‑term volatility or skepticism about pathway/timing to approval and commercial potential. That volatility can pressure shares until a clear registrational plan and larger study data are available. Read More.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.